Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 10/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9670503 | 0.89 | CYP1A2 (0.67) | FFAR1FFAR4CYP1A2 | |
| SCHEMBL20323255 | 0.86 | CYP1A2 (0.66) | FFAR1FFAR4CYP1A2ALDH1A1 | |
| SCHEMBL30403190 | 0.81 | CYP1A2 (0.80) | FFAR1FFAR4CYP1A2 | |
| SCHEMBL11479830 | 0.81 | PTGS1 (0.64) | FFAR1CYP1A2ALDH1A1 | |
| SCHEMBL1217683 | 0.81 | CYP1A2 (0.80) | FFAR1FFAR4CYP1A2 | |
| SCHEMBL12889161 | 0.81 | CYP1A2 (0.59) | FFAR1FFAR4CYP1A2PLA2G10 | |
| SCHEMBL169770 | 0.81 | FFAR1 (0.79) | FFAR1FFAR4ALDH1A1 | |
| SCHEMBL29921611 | 0.80 | HCAR2 (0.57) | FFAR1FFAR4CYP1A2 | |
| Hydrochloric Acid SCHEMBL27401796 | 0.80 | CYP1A2 (0.77) | FFAR1FFAR4CYP1A2 | |
| SCHEMBL151952 | 0.80 | HCAR2 (0.57) | FFAR1FFAR4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219443-A1 | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | Lg Chem, Ltd. (KR) | 2023-08-02 | — | — | EP | disclosed |
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | FFAR1 3/4885FFAR4 16/4885CYP1A2 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.